Hartford Business Journal

www.HartfordBusiness.com March 23, 2015 • Hartford Business Journal 9 The LisT To view the full list, please visit HartfordBusiness.com Real Accountants Real Solutions It's An Art W 280 Trumbull St., Hartford, CT - 14 Bobala Rd., Holyoke, MA www.whcpa.com hittlesey & Hadley accountants are different. We care about our clients, not just their numbers. Our insight and practical advice is original and has been etched into the region's business landscape for more than 50 years. Who wants ordinary out- comes? Our visionary approach to auditing, tax planning, business and technology consulting renders innovative outtcomes that will change the way you do business. Put your trust in advisors with real solutions. Let our knowledge create your next masterpiece. Largest bioscience/biotechnology companies in Connecticut (Ranked by number of employees) Rank Company Headquarters No. of employees in CT No. of R&D employees in CT Focus Year founded Chief executive 1 Pfizer Inc. 558 Eastern Point Rd. Groton, CT 06340 860-441-4100; www.pfizer.com New York, NY 3,000 DND Medicinal chemistry, pharmacokinetics, dynamics and metabolism, pharmaceutical sciences, clinical trial operations, drug safety, comparative medicine, regulatory 1849 Ian C. Read Chairman & CEO 2 Boehringer Ingelheim Pharmaceuticals Inc. 900 Ridgebury Rd. Ridgefield, CT 06877 800-344-3095; us.boehringer-ingelheim.com Ridgefield, CT 2,800 DND Development and manufacture of human and animal healthcare products 1885 Paul R. Fonteyne President & CEO, Boehringer Ingelheim USA 3 Bristol-Myers Squibb Co. 5 Research Pkwy. Wallingford, CT 06492 203-677-6000; www.bms.com New York, NY 925 DND Drug discovery and drug development activities within the following concentrations: applied biotechnology, applied genomics, chemistry, clinical research, metabolism and pharmacokinetics, neuroscience, virology 1858 (1) Lamberto Andreotti CEO 4 Alexion Pharmaceuticals Inc. 352 Knotter Dr. Cheshire, CT 06410 203-272-2596; www.alxn.com Cheshire, CT 750 (2) 210 (2) Severe and life-threatening rare disorders 1992 Leonard Bell (3) Chairman & CEO 5 PerkinElmer Inc. 710 Bridgeport Ave. Shelton, CT 06484 (4) 203-925-4600; www.perkinelmer.com Waltham, MA 500 (5) DND Human and environmental health 1937 Robert F. Friel Chairman & CEO 5 Purdue Pharma LP 1 Stamford Forum, 201 Tresser Blvd. Stamford, CT 06901 800-745-7445; www.purduepharma.com Stamford, CT 500 110 Prescription and non-prescription medicines and hospital products; development of opioid pain medications with abuse- deterrent properties 1991 Mark Timney President & CEO 7 MannKind Corp. 1 Casper St. Danbury, CT 06810 203-798-8000; www.mannkindcorp.com Valencia, CA 221 34 Inhalation product technologies 1991 Hakan Edstrom President, CEO & Director 8 Protein Sciences Corp. 1000 Research Pkwy. Meriden, CT 06450 800-488-7099; www.proteinsciences.com Meriden, CT 140 DND Vaccine development and protein production 1983 Manon M. J. Cox President & CEO 9 The Jackson Laboratory for Genomic Medicine (6) 10 Discovery Drive Farmington, CT 06030 860-856-2474; www.jax.org Bar Harbor, ME 130 DND Genomic causes of and treatments for diseases 2014 (7) Edison T. Liu President & CEO 10 Achillion Pharmaceuticals 300 George St. New Haven, CT 06511 203-624-7000; www.achillion.com New Haven, CT 62 50 Infectious disease and complement-related diseases 1998 Milind S. Deshpande President & CEO 11 Transgenomic Inc. 5 Science Park New Haven, CT 06511 203-907-2201; www.transgenomic.com Omaha, NE 55 3 Genetic testing 1997 Paul Kinnon President & CEO 12 Kolltan Pharmaceuticals Inc. 300 George St., Ste. 530 New Haven, CT 06511 203-773-3000; www.kolltan.com New Haven, CT 39 27 Receptor tyrosine kinases 2007 Gerald McMahon President & CEO 13 Biodel Inc. 100 Saw Mill Rd. Danbury, CT 06810 203-796-5000; www.biodel.com Danbury, CT 35 17 Therapeutics for endocrine disorders 2003 Errol De Souza President & CEO 14 Melinta Therapeutics Inc. 300 George St., Ste. 301 New Haven, CT 06511 203-624-5606; www.melinta.com New Haven, CT 34 29 Discovery, development, and commercialization of antibiotics to overcome resistant, life-threatening infections DND Mary Szela CEO 15 Gilead Connecticut Inc. 36 E. Industrial Rd. Branford, CT 06405 203-315-1222; www.gilead.com Foster City, CA 30 26 HIV/AIDS, liver diseases, cancer and inflammation, respiratory and cardiovascular conditions 1987 John C. Martin Chairman & CEO 16 Ce3 Inc. 246 Goose Ln., Ste. 202 Guilford, CT 06437 203-404-7444; www.ce3inc.com Guilford, CT 25 DND Contract research focused on providing biotechnology companies with Phase 1 – 2 clinical trial execution and regulatory submission services 2005 Holly Ohanesian Coulter President & CEO 17 Arvinas Inc. 5 Science Park, 395 Winchester Ave. New Haven, CT 06511 203-535-1456; www.arvinas.com New Haven CT 22 20 Development of novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease 2013 Manuel Litchman President & CEO 17 AxioMx Inc. 688 E. Main St. Branford, CT 06405 203-208-1918; www.axiomxinc.com Branford, CT 22 9 Recombinant antibody technology development 2012 Christopher McLeod President & CEO 19 NanoViricides Inc. 135 Wood St., Ste. 200 West Haven, CT 06516 203-937-6137; www.nanoviricides.com Shelton, CT 20 15 Nanotechnology-based biomimetic anti-viral medicines targeting influenzas, bird flu, HIV/AIDS, cold sores, genital herpes infection, viral eye diseases, ebola, dengue viruses 2005 Eugene Seymour CEO 20 CARA Therapeutics One Parrott Dr. Shelton, CT 06484 203-567-1500; www.caratherapeutics.com Shelton, CT 16 7 Development of novel therapeutics to treat human diseases associated with pain, inflammation and pruritus 2004 Derek Chalmers Director, President & CEO Source: CURE, each company via survey. Notes: R&D = research and development, DND = did not disclose. While Becton Dickinson and Idexx Laboratories Inc. have R&D operations outside of CT, local facilities are dedicated to manufacturing and thus omitted from this list. Charles River Laboratories International Inc., CooperSurgical Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and Medtronic Inc. (which acquired Covidien PLC) were contacted but did not complete survey. Hologic Inc. has both manufacturing and R&D operations in Danbury, however the company does not disclose employee data by geographic location. (1) Year company was founded. (2) Approximate figure. (3) Effective Apr. 1, 2015 David L. Hallal will assume roll of CEO. Bell will continue to serve as chairman of the board of directors. (4) With an additional R&D operation in Branford. (5) Estimated figure is over 500. (6) On the campus of University of Connecticut Health Center. (7) Year founded for this site; The Jackson Laboratory, headquartered in Maine, was founded in 1929. —Compiled by Roger Magnus and Heide Martin. 2 900 Ridgebury Rd. Ridgefield, CT 06877 800-344-3095; us.boehringer-ingelheim.com Ridgefield, CT 2,800 DND Development and manufacture of human and animal healthcare products 1885 President & CEO, Boehringer Ingelheim USA 3 Bristol-Myers Squibb Co. 5 Research Pkwy. Wallingford, CT 06492 203-677-6000; www.bms.com New York, NY 925 DND Drug discovery and drug development activities within the following concentrations: applied biotechnology, applied genomics, chemistry, clinical research, metabolism and pharmacokinetics, neuroscience, virology 1858 (1) Lamberto Andreotti CEO 4 Alexion Pharmaceuticals Inc. 352 Knotter Dr. Cheshire, CT 06410 203-272-2596; www.alxn.com Cheshire, CT 750 (2) 210 (2) Severe and life-threatening rare disorders 1992 Leonard Bell (3) Chairman & CEO 5 PerkinElmer Inc. 710 Bridgeport Ave. Shelton, CT 06484 (4) 203-925-4600; www.perkinelmer.com Waltham, MA 500 (5) DND Human and environmental health 1937 Robert F. Friel Chairman & CEO 5 Purdue Pharma LP 1 Stamford Forum, 201 Tresser Blvd. Stamford, CT 06901 800-745-7445; www.purduepharma.com Stamford, CT 500 110 Prescription and non-prescription medicines and hospital products; development of opioid pain medications with abuse- deterrent properties 1991 Mark Timney President & CEO 7 MannKind Corp. 1 Casper St. Danbury, CT 06810 203-798-8000; www.mannkindcorp.com Valencia, CA 221 34 Inhalation product technologies 1991 Hakan Edstrom President, CEO & Director 8 Protein Sciences Corp. 1000 Research Pkwy. Meriden, CT 06450 800-488-7099; www.proteinsciences.com Meriden, CT 140 DND Vaccine development and protein production 1983 Manon M. J. Cox President & CEO 9 The Jackson Laboratory for Genomic Medicine (6) 10 Discovery Drive Farmington, CT 06030 860-856-2474; www.jax.org Bar Harbor, ME 130 DND Genomic causes of and treatments for diseases 2014 (7) Edison T. Liu President & CEO 10 Achillion Pharmaceuticals 300 George St. New Haven, CT 06511 203-624-7000; www.achillion.com New Haven, CT 62 50 Infectious disease and complement-related diseases 1998 Milind S. Deshpande President & CEO 11 Transgenomic Inc. 5 Science Park New Haven, CT 06511 203-907-2201; www.transgenomic.com Omaha, NE 55 3 Genetic testing 1997 Paul Kinnon President & CEO 12 Kolltan Pharmaceuticals Inc. 300 George St., Ste. 530 New Haven, CT 06511 203-773-3000; www.kolltan.com New Haven, CT 39 27 Receptor tyrosine kinases 2007 Gerald McMahon President & CEO 13 Biodel Inc. 100 Saw Mill Rd. Danbury, CT 06810 203-796-5000; www.biodel.com Danbury, CT 35 17 Therapeutics for endocrine disorders 2003 Errol De Souza President & CEO 14 Melinta Therapeutics Inc. 300 George St., Ste. 301 New Haven, CT 06511 203-624-5606; www.melinta.com New Haven, CT 34 29 Discovery, development, and commercialization of antibiotics to overcome resistant, life-threatening infections DND Mary Szela CEO 15 Gilead Connecticut Inc. 36 E. Industrial Rd. Branford, CT 06405 203-315-1222; www.gilead.com Foster City, CA 30 26 HIV/AIDS, liver diseases, cancer and inflammation, respiratory and cardiovascular conditions 1987 John C. Martin Chairman & CEO 16 Ce3 Inc. 246 Goose Ln., Ste. 202 Guilford, CT 06437 203-404-7444; www.ce3inc.com Guilford, CT 25 DND Contract research focused on providing biotechnology companies with Phase 1 – 2 clinical trial execution and regulatory submission services 2005 Holly Ohanesian Coulter President & CEO 17 Arvinas Inc. 5 Science Park, 395 Winchester Ave. New Haven, CT 06511 203-535-1456; www.arvinas.com New Haven CT 22 20 Development of novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease 2013 Manuel Litchman President & CEO 17 AxioMx Inc. 688 E. Main St. Branford, CT 06405 203-208-1918; www.axiomxinc.com Branford, CT 22 9 Recombinant antibody technology development 2012 Christopher McLeod President & CEO 19 NanoViricides Inc. 135 Wood St., Ste. 200 West Haven, CT 06516 203-937-6137; www.nanoviricides.com Shelton, CT 20 15 Nanotechnology-based biomimetic anti-viral medicines targeting influenzas, bird flu, HIV/AIDS, cold sores, genital herpes infection, viral eye diseases, ebola, dengue viruses 2005 Eugene Seymour CEO 20 CARA Therapeutics One Parrott Dr. Shelton, CT 06484 203-567-1500; www.caratherapeutics.com Shelton, CT 16 7 Development of novel therapeutics to treat human diseases associated with pain, inflammation and pruritus 2004 Derek Chalmers Director, President & CEO Source: CURE, each company via survey. Notes: R&D = research and development, DND = did not disclose. While Becton Dickinson and Idexx Laboratories Inc. have R&D operations outside of CT, local facilities are dedicated to manufacturing and thus omitted from this list. Charles River Laboratories International Inc., CooperSurgical Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and Medtronic Inc. (which acquired Covidien PLC) were contacted but did not complete survey. Hologic Inc. has both manufacturing and R&D operations in Danbury, however the company does not disclose employee data by geographic location. (1) Year company was founded. (2) Approximate figure. (3) Effective Apr. 1, 2015 David L. Hallal will assume roll of CEO. Bell will continue to serve as chairman of the board of directors. (4) With an additional R&D operation in Branford. (5) Estimated figure is over 500. (6) On the campus of University of Connecticut Health Center. (7) Year founded for this site; The Jackson Laboratory, headquartered in Maine, was founded in 1929. —Compiled by Roger Magnus and Heide Martin.

• Cover